CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: AP1S3 (ImmuneEditome ID:130340)

1. Gene summary of enriched editing regions for AP1S3

check button Gene summary
Gene informationGene symbol

AP1S3

Gene ID

130340

GeneSynonymsPSORS15|sigma1C
GeneCytomap

2q36.1

GeneTypeprotein-coding
GeneDescriptionAP-1 complex subunit sigma-3|adapter-related protein complex 1 subunit sigma-1C|adaptor protein complex AP-1 sigma-1C subunit|adaptor related protein complex 1 sigma 3 subunit|adaptor-related protein complex 1 subunit sigma-1C|clathrin assembly protein complex 1 sigma-1C small chain|golgi adaptor HA1/AP1 adaptin sigma-1C subunit|sigma 1C subunit of AP-1 clathrin
GeneModificationdate20230329
UniprotIDQ96PC3;G5E966;B8ZZZ1;F8W8K9;C9JZK4
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr2:223751688-223757610:-ENST00000443700.4ENSG00000152056.15AP1S3exonicCharlie17,(AAAG)n,AluSx1,AluSp,AluJb,AluSc,AluJr,AluSx,GA-rich,AluJo,AluSq2,AluSzchr2:223751688-223757610:-.alignment
chr2:223770776-223771303:-ENST00000334271.6ENSG00000152056.15AP1S3intronicAluSzchr2:223770776-223771303:-.alignment
chr2:223770776-223771303:-ENST00000396653.2ENSG00000152056.15AP1S3intronicAluSzchr2:223770776-223771303:-.alignment
chr2:223770776-223771303:-ENST00000396654.5ENSG00000152056.15AP1S3intronicAluSzchr2:223770776-223771303:-.alignment
chr2:223770776-223771303:-ENST00000409375.1ENSG00000152056.15AP1S3intronicAluSzchr2:223770776-223771303:-.alignment
chr2:223770776-223771303:-ENST00000415298.4ENSG00000152056.15AP1S3intronicAluSzchr2:223770776-223771303:-.alignment
chr2:223770776-223771303:-ENST00000443700.4ENSG00000152056.15AP1S3intronicAluSzchr2:223770776-223771303:-.alignment
chr2:223770776-223771303:-ENST00000444408.1ENSG00000152056.15AP1S3intronicAluSzchr2:223770776-223771303:-.alignment
chr2:223770776-223771303:-ENST00000446015.5ENSG00000152056.15AP1S3intronicAluSzchr2:223770776-223771303:-.alignment
chr2:223826517-223826792:-ENST00000334271.6ENSG00000152056.15AP1S3intronicAluSz,AluSx4chr2:223826517-223826792:-.alignment
chr2:223826517-223826792:-ENST00000396653.2ENSG00000152056.15AP1S3intronicAluSz,AluSx4chr2:223826517-223826792:-.alignment
chr2:223826517-223826792:-ENST00000396654.5ENSG00000152056.15AP1S3intronicAluSz,AluSx4chr2:223826517-223826792:-.alignment
chr2:223826517-223826792:-ENST00000409375.1ENSG00000152056.15AP1S3intronicAluSz,AluSx4chr2:223826517-223826792:-.alignment
chr2:223826517-223826792:-ENST00000415298.4ENSG00000152056.15AP1S3intronicAluSz,AluSx4chr2:223826517-223826792:-.alignment
chr2:223826517-223826792:-ENST00000443700.4ENSG00000152056.15AP1S3intronicAluSz,AluSx4chr2:223826517-223826792:-.alignment
chr2:223826517-223826792:-ENST00000444408.1ENSG00000152056.15AP1S3intronicAluSz,AluSx4chr2:223826517-223826792:-.alignment
chr2:223826517-223826792:-ENST00000446015.5ENSG00000152056.15AP1S3intronicAluSz,AluSx4chr2:223826517-223826792:-.alignment


Top

2. Tumor-specific enriched editing regions for AP1S3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr2:223751688-223757610:-KIRCEER4.7334e-08image
ENSG00000152056.15,AP1S3KIRCEAG4.6363e-08image
chr2:223751688-223757610:-KIRPEER2.1315e-03image
ENSG00000152056.15,AP1S3KIRPEAG2.1172e-03image
chr2:223751688-223757610:-LUSCEER3.9572e-02image
ENSG00000152056.15,AP1S3LUSCEAG3.9572e-02image
chr2:223751688-223757610:-THCAEER1.1532e-08image
ENSG00000152056.15,AP1S3THCAEAG1.1381e-08image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for AP1S3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:223751688-223757610:-COADEERENSG00000265527,MIR56900.18461.2421e-031.3790e-190.5328imageNNNANeutrophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:223751688-223757610:-COADEERENSG00000222808,RNU4-47P0.24644.1164e-038.5973e-120.4159imageNNNANeutrophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:223751688-223757610:-COADEERENSG00000185591,SP10.24525.0554e-035.7795e-130.4366imageNACIN1;BCCIP;BUD13;CELF2;DDX3X;DDX42;DDX54;EIF4A3;ELAVL1;ELAVL3;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;MSI1;NOP56;NOP58;PTBP1;QKI;RANGAP1;RBFOX2;RBM22;RBM47;SF3B4;SRSF1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;XRN2;YTHDF1;DGCR8;UPF1NANeutrophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:223751688-223757610:-COADEERENSG00000200665,RNU6-1188P0.11875.4150e-031.4442e-180.5198imageNNNANeutrophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:223751688-223757610:-COADEERENSG00000200754,Y_RNA0.14697.3867e-031.6537e-140.4619imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:223751688-223757610:-COADEERENSG00000199990,VTRNA1-10.15517.4224e-034.6236e-120.4208imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:223751688-223757610:-COADEERENSG00000206702,RNU1-11P0.14378.1203e-032.0235e-150.4759imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:223751688-223757610:-COADEERENSG00000169905,TOR1AIP20.23408.2191e-031.3617e-120.4302imageNACIN1;BCCIP;BUD13;CELF2;DDX3X;DDX42;DDX54;EIF4A3;ELAVL1;ELAVL3;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;MSI1;NOP56;NOP58;PTBP1;QKI;RANGAP1;RBFOX2;RBM22;RBM47;SF3B4;SRSF1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;XRN2;YTHDF1;DGCR8;UPF1NAEosinophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr2:223751688-223757610:-COADEERENSG00000212242,RNA5SP2190.22758.3770e-033.2494e-150.4728imageNNNANeutrophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:223751688-223757610:-COADEERENSG00000201662,RNU6-60P0.12761.4117e-022.7002e-160.4887imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP

More results



Top

4. Enriched editing regions and immune related splicing for AP1S3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:223751688-223757610:-
COADEERIRENSG00000075856.7chr12108537105:108537595:108538064:1085381320.22993.8846e-024.3164e-160.4866imageNACIN1;BCCIP;BUD13;CELF2;DDX3X;DDX42;DDX54;EIF4A3;ELAVL1;ELAVL3;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;MSI1;NOP56;NOP58;PTBP1;QKI;RANGAP1;RBFOX2;RBM22;RBM47;SF3B4;SRSF1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;XRN2;YTHDF1;DGCR8;UPF1SART3EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000152056.15,AP1S3
COADEAGIRENSG00000085832.12chr151446959:51447105:51448045:514481350.23272.7147e-021.0528e-180.5337imageNACIN1;ADAR;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;YTHDC1;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000152056.15,AP1S3
COADEAGIRENSG00000136153.15chr1375856480:75856608:75857920:758581560.23323.4267e-025.2895e-180.5124imageNACIN1;ADAR;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;VIM;YTHDC1;ZC3H7B;ZNF184LMO7Mast_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:223751688-223757610:-
COADEERIRENSG00000116977.14chr1236538878:236539089:236540563:2365406830.23103.9463e-027.2644e-160.4825imageNBCCIP;BUD13;CELF2;DDX3X;DDX42;DDX54;ELAVL1;ELAVL3;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;KHDRBS2;NOP56;NOP58;PTBP1;QKI;RBFOX2;RBM22;RBM47;SF3B4;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;XRN2;YTHDF1;DGCR8;UPF1LGALS8EosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:223751688-223757610:-
COADEERA3ENSG00000071242.7chr6166451102:166451233:166448723:166448846:166448723:1664488490.05193.9624e-023.2681e-120.4657imageNACIN1;BCCIP;CELF2;DDX42;DDX54;EIF4A3;ELAVL1;ELAVL3;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;MSI1;NOP56;NOP58;PTBP1;QKI;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;U2AF2;XRN2;DGCR8;UPF1RPS6KA2Dendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000152056.15,AP1S3
COADEAGIRENSG00000116977.14chr1236538878:236539089:236540563:2365406830.22864.8608e-023.7959e-180.5143imageNADAR;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28B;MBNL2;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;YTHDC1LGALS8EosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000152056.15,AP1S3
COADEAGIRENSG00000109332.15chr4102826484:102826636:102827426:1028275000.23243.4714e-025.1035e-120.4208imageNACIN1;ADAR;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;RC3H1;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;VIM;YTHDC1;ZC3H7B;ZNF184UBE2D3EosinophilsGSVA_HALLMARK_PEROXISOME
ENSG00000152056.15,AP1S3
COADEAGMEXENSG00000019582.10chr5150401863:150402004:150406258:150406412:150406910:150406960:150407151:1504073240.24292.7786e-029.3610e-120.4152imageNADAR;BCCIP;BUD13;CSTF2T;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28A;LIN28B;MBNL1;MBNL2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;PUM2;QKI;RBFOX2;RBM47;RBM5;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;YTHDC1CD74Dendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
ENSG00000152056.15,AP1S3
COADEAGIRENSG00000087074.7chr1948872391:48872651:48873224:488734790.23303.4761e-029.8015e-260.6019imageNACIN1;BCCIP;BUD13;CAPRIN1;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;VIM;YTHDC1;ZNF184PPP1R15AEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000152056.15,AP1S3
COADEAGIRENSG00000135945.5chr299400949:99403106:99403694:994038150.23254.2462e-021.2683e-180.5205imageNACIN1;ADAR;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;VIM;YTHDC1;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP

More results



Top

5. Enriched editing regions and immune infiltration for AP1S3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr2:223751688-223757610:-BLCAEERMacrophages_M13.1059e-060.2535image
ENSG00000152056.15,AP1S3BLCAEAGMacrophages_M13.1059e-060.2535image
chr2:223751688-223757610:-BRCAEERT_cells_regulatory_(Tregs)8.2187e-040.1110image
ENSG00000152056.15,AP1S3BRCAEAGT_cells_regulatory_(Tregs)8.4969e-040.1106image
chr2:223751688-223757610:-CESCEERB_cells_naive3.8071e-03-0.1749image
ENSG00000152056.15,AP1S3CESCEAGB_cells_naive3.8071e-03-0.1749image
chr2:223751688-223757610:-CHOLEERT_cells_CD4_naive1.7109e-020.4186image
ENSG00000152056.15,AP1S3CHOLEAGT_cells_CD4_naive1.7109e-020.4186image
chr2:223751688-223757610:-COADEERMast_cells_activated2.3463e-020.1439image
ENSG00000152056.15,AP1S3COADEAGNeutrophils7.5940e-030.1692image
chr2:223751688-223757610:-DLBCEERT_cells_gamma_delta8.7279e-030.3997image
ENSG00000152056.15,AP1S3DLBCEAGT_cells_gamma_delta8.7279e-030.3997image
chr2:223751688-223757610:-ESCAEERMonocytes3.0153e-03-0.2353image
ENSG00000152056.15,AP1S3ESCAEAGMonocytes5.7258e-03-0.2196image
chr2:223751688-223757610:-GBMEERT_cells_CD81.9903e-020.4161image
ENSG00000152056.15,AP1S3GBMEAGT_cells_CD81.9903e-020.4161image
chr2:223751688-223757610:-HNSCEERMacrophages_M11.1456e-020.1209image
ENSG00000152056.15,AP1S3HNSCEAGMacrophages_M11.1456e-020.1209image
chr2:223751688-223757610:-KICHEERT_cells_regulatory_(Tregs)4.6916e-020.2742image
ENSG00000152056.15,AP1S3KICHEAGT_cells_regulatory_(Tregs)4.6916e-020.2742image
chr2:223751688-223757610:-KIRCEERT_cells_gamma_delta2.1862e-030.1597image
ENSG00000152056.15,AP1S3KIRCEAGT_cells_gamma_delta1.7726e-030.1629image
chr2:223751688-223757610:-KIRPEERDendritic_cells_activated3.3201e-020.1280image
ENSG00000152056.15,AP1S3KIRPEAGDendritic_cells_activated3.3334e-020.1279image
ENSG00000152056.15,AP1S3LAMLEAGT_cells_CD4_memory_resting3.7150e-020.4276image
chr2:223751688-223757610:-LUADEERT_cells_CD4_memory_activated3.3593e-040.1630image
ENSG00000152056.15,AP1S3LUADEAGT_cells_CD4_memory_activated3.3317e-040.1631image
chr2:223751688-223757610:-LUSCEERT_cells_CD4_memory_activated1.2627e-060.2241image
ENSG00000152056.15,AP1S3LUSCEAGT_cells_CD4_memory_activated1.2627e-060.2241image
chr2:223751688-223757610:-MESOEERMacrophages_M14.6841e-020.2334image
ENSG00000152056.15,AP1S3MESOEAGMacrophages_M14.6841e-020.2334image
chr2:223751688-223757610:-OVEERB_cells_naive1.4074e-02-0.1646image
ENSG00000152056.15,AP1S3OVEAGB_cells_naive1.3811e-02-0.1651image
chr2:223751688-223757610:-PAADEERT_cells_CD4_memory_resting4.9497e-02-0.1518image
ENSG00000152056.15,AP1S3PAADEAGT_cells_CD4_memory_resting4.9497e-02-0.1518image
chr2:223751688-223757610:-PRADEERDendritic_cells_activated2.9756e-070.2340image
ENSG00000152056.15,AP1S3PRADEAGDendritic_cells_activated2.8313e-070.2344image
chr2:223751688-223757610:-SARCEERT_cells_CD82.4270e-030.6128image
ENSG00000152056.15,AP1S3SARCEAGT_cells_CD82.4270e-030.6128image
chr2:223751688-223757610:-SKCMEERT_cells_CD81.0943e-040.2142image
ENSG00000152056.15,AP1S3SKCMEAGT_cells_CD81.0943e-040.2142image
chr2:223751688-223757610:-STADEEREosinophils7.6200e-070.2618image
chr2:223770776-223771303:-STADEERT_cells_CD4_memory_activated2.4015e-020.3288image
ENSG00000152056.15,AP1S3STADEAGEosinophils4.9305e-070.2660image
chr2:223751688-223757610:-THCAEERT_cells_regulatory_(Tregs)3.9318e-020.0920image
ENSG00000152056.15,AP1S3THCAEAGT_cells_regulatory_(Tregs)3.8899e-020.0922image
chr2:223751688-223757610:-THYMEERPlasma_cells4.5697e-030.3555image
ENSG00000152056.15,AP1S3THYMEAGPlasma_cells4.5697e-030.3555image
chr2:223751688-223757610:-UCSEERNeutrophils3.7270e-02-0.3437image
ENSG00000152056.15,AP1S3UCSEAGNeutrophils3.7270e-02-0.3437image
chr2:223751688-223757610:-UVMEERMast_cells_activated2.2713e-060.7731image
ENSG00000152056.15,AP1S3UVMEAGMast_cells_activated2.2713e-060.7731image


Top

6. Enriched editing regions and immune gene sets for AP1S3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr2:223751688-223757610:-BLCAEER4.7719e-02image3.1768e-040.1970image
ENSG00000152056.15,AP1S3BLCAEAG4.7719e-02image3.1768e-040.1970image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000152056.15,AP1S3COADEAG9.6071e-04-0.20844.4946e-02-0.12742.1566e-06-0.29561.0865e-02-0.1615image
chr2:223751688-223757610:-COADEER1.2422e-03-0.20394.9071e-02-0.12512.6658e-06-0.29309.5540e-03-0.1643image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr2:223751688-223757610:-BLCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.3325e-050.2372image
ENSG00000152056.15,AP1S3BLCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.3325e-050.2372image
ENSG00000152056.15,AP1S3BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4440e-130.2421image
chr2:223751688-223757610:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3173e-130.2426image
ENSG00000152056.15,AP1S3CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.1619e-050.2495image
chr2:223751688-223757610:-CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.1619e-050.2495image
ENSG00000152056.15,AP1S3CHOLGSVA_HALLMARK_P53_PATHWAYEAG1.1958e-02-0.4390image
chr2:223751688-223757610:-CHOLGSVA_HALLMARK_P53_PATHWAYEER1.1958e-02-0.4390image
ENSG00000152056.15,AP1S3COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG9.8107e-08-0.3306image
chr2:223751688-223757610:-COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER9.0150e-08-0.3315image
chr2:223751688-223757610:-DLBCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.3510e-030.4569image
ENSG00000152056.15,AP1S3DLBCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.3510e-030.4569image
ENSG00000152056.15,AP1S3ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.8397e-050.3346image
chr2:223751688-223757610:-ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.3690e-050.3305image
ENSG00000152056.15,AP1S3GBMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.9308e-020.3917image
chr2:223751688-223757610:-GBMGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.9308e-020.3917image
chr2:223751688-223757610:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6590e-080.2622image
ENSG00000152056.15,AP1S3HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.6590e-080.2622image
ENSG00000152056.15,AP1S3KICHGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.9025e-030.3899image
chr2:223751688-223757610:-KICHGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.9025e-030.3899image
ENSG00000152056.15,AP1S3KIRPGSVA_HALLMARK_UV_RESPONSE_DNEAG8.0690e-04-0.2002image
chr2:223751688-223757610:-KIRPGSVA_HALLMARK_UV_RESPONSE_DNEER8.1321e-04-0.2000image
ENSG00000152056.15,AP1S3LAMLGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.2130e-02-0.5035image
chr2:223751688-223757610:-LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.8020e-040.1701image
ENSG00000152056.15,AP1S3LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.7839e-040.1703image
chr2:223751688-223757610:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.2026e-070.2270image
ENSG00000152056.15,AP1S3LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.2026e-070.2270image
ENSG00000152056.15,AP1S3MESOGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.7698e-02-0.2438image
chr2:223751688-223757610:-MESOGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.7698e-02-0.2438image
chr2:223751688-223757610:-OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.4420e-030.1903image
ENSG00000152056.15,AP1S3OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG4.5503e-030.1898image
ENSG00000152056.15,AP1S3PAADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.0812e-03-0.2500image
chr2:223751688-223757610:-PAADGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.0812e-03-0.2500image
ENSG00000152056.15,AP1S3PRADGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.5474e-09-0.2707image
chr2:223751688-223757610:-PRADGSVA_HALLMARK_PROTEIN_SECRETIONEER5.0401e-09-0.2658image
ENSG00000152056.15,AP1S3READGSVA_HALLMARK_UV_RESPONSE_UPEAG1.0457e-02-0.2732image
chr2:223751688-223757610:-READGSVA_HALLMARK_UV_RESPONSE_UPEER1.0457e-02-0.2732image
ENSG00000152056.15,AP1S3SARCGSVA_HALLMARK_APICAL_JUNCTIONEAG3.7931e-020.4451image
chr2:223751688-223757610:-SARCGSVA_HALLMARK_APICAL_JUNCTIONEER3.7931e-020.4451image
chr2:223751688-223757610:-SKCMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.2939e-040.2120image
ENSG00000152056.15,AP1S3SKCMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.2939e-040.2120image
ENSG00000152056.15,AP1S3STADGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG1.0544e-020.1371image
chr2:223751688-223757610:-STADGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER4.9159e-030.1507image
chr2:223751688-223757610:-TGCTGSVA_HALLMARK_KRAS_SIGNALING_UPEER3.6848e-020.4473image
ENSG00000152056.15,AP1S3TGCTGSVA_HALLMARK_KRAS_SIGNALING_UPEAG3.6848e-020.4473image
chr2:223751688-223757610:-THCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.4982e-05-0.1869image
ENSG00000152056.15,AP1S3THCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.4878e-05-0.1870image
chr2:223751688-223757610:-UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.9149e-030.2414image
ENSG00000152056.15,AP1S3UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.9051e-030.2415image
chr2:223751688-223757610:-UCSGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER8.3522e-030.4273image
ENSG00000152056.15,AP1S3UCSGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG8.3522e-030.4273image
ENSG00000152056.15,AP1S3UVMGSVA_HALLMARK_PROTEIN_SECRETIONEAG7.9727e-03-0.4996image
chr2:223751688-223757610:-UVMGSVA_HALLMARK_PROTEIN_SECRETIONEER7.9727e-03-0.4996image


Top

7. Enriched editing regions and drugs for AP1S3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000152056.15,AP1S3BLCACGP.60474EAG1.1102e-06-0.2644image
chr2:223751688-223757610:-BLCACGP.60474EER1.1102e-06-0.2644image
chr2:223751688-223757610:-BRCAFTI.277EER3.1515e-030.0980image
ENSG00000152056.15,AP1S3BRCAFTI.277EAG3.2109e-030.0978image
chr2:223751688-223757610:-CESCCGP.082996EER5.4478e-05-0.2421image
ENSG00000152056.15,AP1S3CESCCGP.082996EAG5.4478e-05-0.2421image
chr2:223751688-223757610:-CHOLAKT.inhibitor.VIIIEER9.8473e-04-0.5547image
ENSG00000152056.15,AP1S3CHOLAKT.inhibitor.VIIIEAG9.8473e-04-0.5547image
ENSG00000152056.15,AP1S3COADCCT007093EAG2.5690e-06-0.2935image
chr2:223751688-223757610:-COADAZ628EER6.7715e-060.2814image
chr2:223751688-223757610:-DLBCDoxorubicinEER1.6193e-050.6126image
ENSG00000152056.15,AP1S3DLBCDoxorubicinEAG1.6193e-050.6126image
ENSG00000152056.15,AP1S3ESCAAZD.2281EAG1.2723e-05-0.3416image
chr2:223751688-223757610:-ESCAAZD.2281EER8.6217e-05-0.3091image
ENSG00000152056.15,AP1S3GBMABT.263EAG1.2516e-02-0.4432image
chr2:223751688-223757610:-GBMABT.263EER1.2516e-02-0.4432image
chr2:223751688-223757610:-HNSCCGP.082996EER1.6674e-08-0.2659image
ENSG00000152056.15,AP1S3HNSCCGP.082996EAG1.6674e-08-0.2659image
ENSG00000152056.15,AP1S3KICHDasatinibEAG3.5544e-03-0.3935image
chr2:223751688-223757610:-KICHDasatinibEER3.5544e-03-0.3935image
chr2:223751688-223757610:-KIRCDMOGEER3.6227e-03-0.1517image
ENSG00000152056.15,AP1S3KIRCDMOGEAG3.5434e-03-0.1521image
chr2:223751688-223757610:-KIRPAS601245EER1.6366e-060.2834image
ENSG00000152056.15,AP1S3KIRPAS601245EAG1.6060e-060.2836image
ENSG00000152056.15,AP1S3LAMLBosutinibEAG4.0224e-02-0.4215image
ENSG00000152056.15,AP1S3LIHCJNJ.26854165EAG3.4532e-03-0.3402image
chr2:223751688-223757610:-LIHCJNJ.26854165EER3.4532e-03-0.3402image
ENSG00000152056.15,AP1S3LUADJNK.Inhibitor.VIIIEAG7.7805e-05-0.1793image
chr2:223751688-223757610:-LUADJNK.Inhibitor.VIIIEER7.7802e-05-0.1793image
chr2:223751688-223757610:-LUSCIPA.3EER8.2788e-07-0.2279image
ENSG00000152056.15,AP1S3LUSCIPA.3EAG8.2788e-07-0.2279image
chr2:223751688-223757610:-OVABT.263EER3.3306e-040.2387image
ENSG00000152056.15,AP1S3OVABT.263EAG3.4762e-040.2380image
chr2:223751688-223757610:-PAADAZD6482EER8.1973e-050.3035image
ENSG00000152056.15,AP1S3PAADAZD6482EAG8.1973e-050.3035image
ENSG00000152056.15,AP1S3PCPGAMG.706EAG2.8044e-020.2442image
chr2:223751688-223757610:-PCPGAMG.706EER2.8044e-020.2442image
ENSG00000152056.15,AP1S3PRADKU.55933EAG2.9307e-05-0.1917image
chr2:223751688-223757610:-PRADKU.55933EER3.9306e-05-0.1886image
chr2:223751688-223757610:-READBMS.754807EER9.2038e-03-0.2777image
ENSG00000152056.15,AP1S3READBMS.754807EAG9.2038e-03-0.2777image
chr2:223751688-223757610:-SARCBI.2536EER5.4787e-03-0.5713image
ENSG00000152056.15,AP1S3SARCBI.2536EAG5.4787e-03-0.5713image
ENSG00000152056.15,AP1S3SKCMDasatinibEAG3.1922e-03-0.1654image
chr2:223751688-223757610:-SKCMDasatinibEER3.1922e-03-0.1654image
ENSG00000152056.15,AP1S3STADGNF.2EAG1.2255e-02-0.1343image
chr2:223751688-223757610:-STADGNF.2EER7.8777e-03-0.1424image
chr2:223751688-223757610:-TGCTEmbelinEER2.7641e-030.6066image
ENSG00000152056.15,AP1S3TGCTEmbelinEAG2.7641e-030.6066image
ENSG00000152056.15,AP1S3THCAEmbelinEAG2.4123e-060.2087image
chr2:223751688-223757610:-THCAEmbelinEER2.4245e-060.2086image
chr2:223751688-223757610:-THYMAZD6244EER2.2759e-05-0.5102image
ENSG00000152056.15,AP1S3THYMAZD6244EAG2.2759e-05-0.5102image
ENSG00000152056.15,AP1S3UCECLFM.A13EAG1.2077e-02-0.2045image
chr2:223751688-223757610:-UCECLFM.A13EER1.2036e-02-0.2046image
chr2:223751688-223757610:-UCSBIBW2992EER2.0698e-030.4902image
ENSG00000152056.15,AP1S3UCSBIBW2992EAG2.0698e-030.4902image
chr2:223751688-223757610:-UVMAZD.0530EER1.3618e-03-0.5846image
ENSG00000152056.15,AP1S3UVMAZD.0530EAG1.3618e-03-0.5846image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType